The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program.
Publication/Presentation Date
9-1-2012
Abstract
OBJECTIVE: The C allele at the rs11212617 polymorphism in the ataxia-telangiectasia-mutated (ATM) gene has been associated with greater clinical response to metformin in people with type 2 diabetes. We tested whether this variant modified the effect of metformin in the Diabetes Prevention Program (DPP), in which metformin reduced diabetes incidence by 31% in volunteers with impaired glucose tolerance.
RESEARCH DESIGN AND METHODS: We genotyped rs11212617 in 2,994 DPP participants and analyzed its effects on diabetes incidence and related traits.
RESULTS: Contrary to expectations, C carriers enjoyed no preventive advantage on metformin; their hazard ratio, compared with A carriers, was 1.17 ([95% CI 0.96-1.42], P = 0.13) under metformin. There were no significant differences by genotype in metformin's effects on insulin sensitivity, fasting glucose, glycated hemoglobin, or disposition index.
CONCLUSIONS: The reported association of rs11212617 with metformin response was not confirmed for diabetes prevention or for effects on relevant physiologic parameters in the DPP.
Volume
35
Issue
9
First Page
1864
Last Page
1867
ISSN
1935-5548
Published In/Presented At
Florez, J. C., Jablonski, K. A., Taylor, A., Mather, K., Horton, E., White, N. H., Barrett-Connor, E., Knowler, W. C., Shuldiner, A. R., Pollin, T. I., & Diabetes Prevention Program Research Group (2012). The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes care, 35(9), 1864–1867. https://doi.org/10.2337/dc11-2301
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
22751958
Department(s)
Administration and Leadership
Document Type
Article